Skip to main content
. Author manuscript; available in PMC: 2022 Nov 1.
Published in final edited form as: Drug Alcohol Depend. 2021 Aug 27;228:108985. doi: 10.1016/j.drugalcdep.2021.108985

Figure 5.

Figure 5.

Effects of the α1GABAA antagonist βCCT during chronic alprazolam treatment (1.0 mg/kg/4 h, or 6.0 mg/kg/day, i.v.) in rhesus monkeys (N=4). Top panel: Time-dependent effects of βCCT, βCCT vehicle (note that chronic alprazolam injections continued during these tests), or the 3.0 mg/kg dose of βCCT tested prior to chronic alprazolam treatment (“βCCT alone”). Data are mean ± SEM for a combined score of all withdrawal-related behaviors (see Table 2). *Note that p< 0.05 vs. Vehicle (alprazolam) treatment (Bonferroni t-tests). Bottom panel: Distribution of individual withdrawal-associated behaviors (see Table 1) that constituted the average combined score at the time points after βCCT injections that were statistically significant compared to corresponding vehicle data. Each individual behavior is the mean across monkeys (error bars are not shown for clarity).